louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01211041: The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia
Official title: The Relationship Between Morphology and Virulent Genes of Candida Albicans and Clinical Aspects, Surveillance of Fungemia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Candidemia Prognostic Factor and Mycobiological Analysis.
Keywords: Candida albicans, fungemia , prognostic factor
Lead sponsor: Taipei Medical University WanFang Hospital
Sponsor class: OTHER
First posted: 2010-09-29
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: case with candidemia of Candida albicans and candida caused the disease .

Brief summary: Candida albicans is the most common and important clinical fungal pathogen. Our previous surveillance disclosed that fluconazole could induce different morphological changes in clinical strains. Our current study on C. albicans causing candiuria disclosed that renal insufficiency , diabetes mellitus, respiratory failure and uremia were risk factors of treatment failure. However, we also found results of E-test drug susceptible test could not predict outcome. Hence, retrospective analysis of 31 months period, cases that had C. albicans inducing candidemia were reviewed and 60 cases were enrolled for morphological study and potential virulent gene analysis.

This study is designed to clarity the clinical meaning of morphological form and virulent genes on candidemia. To do this study is probably helpful for treatment of candidiasis.


Eligibility criteria: Inclusion Criteria:

* 2007 to 2010 medical records
* Cases with candidemmia of Candida albicans with available clinical information in medical records for analysis.
* Cases with candidemmia of Candida albicans which clinical isolates were preserved.

Exclusion Criteria:

* Cases were not hospitalized for treatment and data were not available for analysis.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei Medical University - WanFang Hospital
Study officials:
affiliation: Taipei Medical University WanFang Hospital
name: Tsong-Yih Ou
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02798341: The Breast Program - Translational Cancer Resource
Official title: The Breast Program - Translational Cancer Resource
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Breast Cancer
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2016-06-14
Enrollment: 4000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Breast Cancer

Brief summary: TRACR will provide a data/biospecimen repository for translational research to better diagnose, prognose, treat and cure breast cancer (and related diseases/treatment conditions). Patients at the Rowan Breast Center will be consented for donation of blood and if available tumor/healthy/archived tissue. Patients will be consented to give permission to use said specimens for future research and to be contacted in the future about other research participation and additional information.


Eligibility criteria: Inclusion Criteria:

* RBC patients with known invasive cancer pre-surgery (greater or equal to 1.5cm) are given priority in recruitment.
* RBC patients with known invasive cancer pre-surgery (less then 1.5cm). 3. RBC patients who are postsurgery for invasive breast cancer (performed at UPHS or non-UPHS entities).
* Patients that are of high risk for breast cancer (family history, known deleterious genetic mutation(s)) seeking a prophylactic mastectomy at the breast clinic.
* Only persons who can understand and give informed consent will be eligible to participate in this study. Furthermore, no persons belonging to vulnerable populations with as children (below 18 years of age), fetuses, neonates or prisoners will be recruited in this study. Pregnant women, who are pre-surgery and having surgery for clinical reasons, can still be recruited for tissue and blood collection.

Exclusion Criteria:

* Individual who cannot understand and give informed consent (cognitively impaired persons)
* Children (below 18 years of age), fetuses and neonates
* Prisoners

Primary outcomes:
measure: Number of biospecimen collected
timeFrame: 15 years
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center of the University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Angela DeMichele, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04267341: Effect of Dual Task on Upper and Lower Extremity Skills in Parkinson's Disease
Official title: Examining The Change of Upper and Lower Extremity Skills With The Effect of Dual Task in Parkinson's Disease Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson Disease
Movement Disorders
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2020-02-12
Enrollment: 45
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with Parkinson's Disease who apply to the Hacettepe University, Faculty of Physiotherapy and Rehabilitation, Department of Neurological Rehabilitation will be invited to this study.

Brief summary: The aim of the study is to investigate the change of lower and upper extremity skills with dual task in Parkinson's disease patients and to determine the differences between Parkinson's disease patients with different stages of disease and the healthy controls regarding the change of lower and upper extremity skills with dual task.


Eligibility criteria: Inclusion Criteria:

* Modified Hoehn \& Yahr (H\&Y) stages 1 to 3
* at least 40 years of age
* 21 or more MoCA score.

Exclusion Criteria:

* other neurologic disorder
* any orthopedic problem that could prevent to participate in the study
* severe dyskinesia or tremor
* visual or speech problems

Primary outcomes:
measure: Timed Up and Go Test
timeFrame: 10-15 seconds
measure: 10 Meter Walk Test
timeFrame: 10-15 seconds
measure: Purdue Pegboard Test
timeFrame: 3-5 minutes
Secondary outcomes:
measure: Modified Hoehn and Yahr Scale
timeFrame: 1 minute
measure: Montreal Cognitive Assessment (MoCA)
timeFrame: 10-15 minutes
measure: Short-Form 8-Item Parkinson's Disease Questionnaire (PDQ-8)
timeFrame: 1-2 minutes
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University, Faculty of Physical Therapy and Rehabilitation
Study officials:
References:
Clinical trial NCT03149341: MRI and Computational Simulation Cardiology Study
Official title: MR Imaging and Computational Simulation of Cardiovascular Physiology Including Velocity, Pressure, and Wall Shear Stress
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Congenital Heart Disease
Pulmonary Hypertension
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2017-05-11
Enrollment: 75
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: LPCH and Stanford clinics

Brief summary: The purpose of this study is to (1) quantify cardiovascular anatomy and physiology using magnetic resonance imaging under both resting and exercise conditions in patients who have congenital heart disease and in age-matched normal volunteers, (2) use computer models to reproduce and simulate blood flow in these patients, and then (3) to combine the imaging data and computer models to estimate values which cannot be directly measured and to predict physiological changes induced by exercise and medical or surgical therapies.

Detailed description: Investigators hope to gain a greater understanding of the hemodynamics of congenital heart disease and their associated operations as they pertain to real-life situations (i.e. upright and non-sedentary, rest and exercise). With this knowledge, investigators would look to optimize the geometry and physiology of the patients, potentially reducing several of the long-term complications found in congenital heart disease patients such as cardiomyopathy, pulmonary hypertension, arrhythmias, thrombosis and heart failure.

Eligibility criteria: Inclusion Criteria:

* patients will have congenital heart disease or acquired cardiopulmonary disease.
* normal volunteers will be willing to undergo MRI

Exclusion Criteria:

* patients unable to receive intravenous contrast material (this does not apply to normal volunteers)
* subjects with arrhythmias which will prevent MRI cardiac gating
* subjects with illnesses which make participation inappropriate. In addition, patients who would normally be excluded from an MRI study because of pacemaker implant, aneurysm clip, severe claustrophobia, or any other condition which, based on the Investigator's judgment, would preclude proximity to a strong magnetic field will be excluded from this study as well.
* NORMAL VOLUNTEERS may be excluded if they are not able to remain still during the exam or follow the instructions of the investigators.

Primary outcomes:
measure: Wall Shear Stress
timeFrame: 20 years
Secondary outcomes:
Other outcomes:
Locations:
city: Palo Alto
country: United States
facility: Lucile Packard Children's Hospital at Stanford
state: California
Study officials:
affiliation: Stanford University
name: Jeffrey Feinstein, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02070341: Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose PEG
Official title: A Randomized Controlled Trial Examining Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose Polyethylene Glycol
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Bowel Preparation
Keywords: patient tolerability
quality
Lead sponsor: Queen's University
Sponsor class: OTHER
First posted: 2014-02-25
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Introduction: Colonoscopy is an important tool for colon cancer screening. Proper colon cleansing is essential to ensure adequate mucosal examination. Timing of bowel preparation administration is now recognized as an important component for achieving superior cleansing. Multiple randomized controlled trials and meta-analyses have found split-dosing to be superior than day-before dosing. Objective: This study aims to compare two types of bowel preparations in split-doses to assess for differences in patient tolerability, as well as efficacy of colon cleansing. Methods: This is a prospective, single-blinded, randomized-controlled trial. Patients who are being referred for a colonoscopy will be recruited to participate in the study. They will be randomly assigned to receive either a split-dose polyethylene glycol (PEG) or picosalax (P/MC) bowel preparation. Patient tolerability will be examined through questionnaires. The endoscopist performing the colonoscopy will use two standardized bowel preparation scoring systems to evaluate the quality of the cleansing. The investigators propose that P/MC will be superior to PEG in patient tolerability and non-inferior in bowel cleansing effects.


Eligibility criteria: Inclusion Criteria:

* All male and non-pregnant female patients between ages 18 and 75 years old who require outpatient colonoscopy

Exclusion Criteria:

* ileus or bowel obstruction, previous colorectal surgery, ascites, recognized renal impairment, defined as GFR less than normal in 3 months prior to enrollment, active inflammatory bowel disease, insulin dependent diabetes, pregnancy, or recent (\<6 months) myocardial infarction or unstable angina

Primary outcomes:
measure: Patient tolerability
timeFrame: Two days
Secondary outcomes:
measure: Quality of bowel preparation
timeFrame: During colonoscopy
Other outcomes:
Locations:
city: Kingston
country: Canada
facility: Hotel Dieu Hospital
state: Ontario
Study officials:
affiliation: Queen's University
name: Lawrence Hookey
role: PRINCIPAL_INVESTIGATOR
affiliation: Queen's University
name: Stephen Vanner
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06998641: EFFECTİVİTY OF CHITOSAN COVERED GAUZE IN POSTPARTUM HEMORRHAGIC OBSTETRIC LACERATIONS
Official title: EFFECTİVİTY OF CHITOSAN COVERED GAUZE IN POSTPARTUM HEMORRHAGIC OBSTETRIC LACERATIONS
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Effectiveness of Chitosan Covered Gauze to Stop Bleeding in Post-partum Tears
Comparison of the Effect of Chitosan Covered Gauze With Suturing in Terms of Hemostasis in Post-partum Haemorrhagic Tears
Keywords: chitosan-covered-gauze
post-partum lacerations
obstetrical tears
Lead sponsor: Istanbul Training and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2025-05-31
Enrollment: 62
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 48
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was planned to investigate the efficacy of different treatment methods that can be used in the treatment of hemorrhagic tears that may occur in the postpartum period. The volunteers who will participate in the study will be evaluated during the hospitalization period after delivery and at the end of the puerperium 6 weeks after delivery, in accordance with routine postpartum control examinations. In the treatment of postpartum hemorrhagic tears, the treatment options such as suturing the tears to stop bleeding or applying tampons with bleeding stopping agent (chitosan) and compression effect to the torn area will be determined completely randomly.


Eligibility criteria: Inclusion Criteria: Patients, 18-48 years old, who gave birth in Istanbul TRH between March 2025 and March 2027 experiencing 1st and 2nd degree obstetric lacerations with postpartum hemorrhage without the need for anatomical defect repairing and without additional conditions such as uterine atony, placental rest, etc. that may affect the amount of postpartum bleeding.

Exclusion Criteria: Patients not fullfilling the inclusion criteria in terms of age limits, time and place of birth or ones who are experiencing 1st and 2nd degree obstetric lacerations with postpartum hemorrhage with the need for anatomical defect repairing and with additional conditions such as uterine atony, placental rest, etc. that may affect the amount of postpartum bleeding.

Primary outcomes:
measure: Amount of bleeding
timeFrame: From time of birth to the cessation of bleeding
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Istanbul Training and Research Hospital Department of Obstetrics and Gynecology
Study officials:
References:
Clinical trial NCT07022041: Sepsis and Hospital Mortality
Official title: Sepsis and In-Hospital Mortality: A Quality Indicator in Acute Care Settings
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Sepsis
Lead sponsor: University of Calabria
Sponsor class: OTHER
First posted: 2025-06-15
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult cardiac patients aged 18 years and older, both with and without infections, are considered, while those with severe comorbidities or undergoing treatments that may influence the study outcomes are excluded.

Brief summary: Sepsis is one of the leading causes of hospital mortality, with a mortality rate of 20% (World Health Organization) among vulnerable patients admitted to high-intensity care units such as CCUs and inpatient wards.

Currently, diagnostic criteria such as Systemic Inflammatory Response Syndrome (SIRS) and the Sequential Organ Failure Assessment (SOFA) score, although widely used, lack specificity and accuracy. There are no established parameters for early and timely diagnosis.

This project aims to address this gap by investigating the variability of blood plasma conductivity and dielectric constant using microwave probes already validated for non-invasive glucose monitoring.

The data acquired will be processed using the Anritsu VectorStar VNA, in order to identify innovative and reliable parameters associated with the presence of severe infections.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Cardiology patients without infection (Control Group)
* Patients with sepsis
* Patients with nosocomial infection
* Patients with myocarditis, endocarditis, or pericarditis
* Ability to provide written informed consent

Exclusion Criteria:

* Patients with severe or chronic medical conditions that may interfere with study results, such as autoimmune diseases, renal or hepatic failure
* Patients taking medications that could affect the measured biophysical parameters, such as corticosteroids or immunosuppressants
* Patients with cancer
* Patients with diseases involving the immune system (e.g., lymphomas, leukemias)
* Patients with congenital or acquired immunodeficiencies (e.g., HIV)
* Patients who are unable to read and sign the informed consent form

Primary outcomes:
measure: Comparative Analysis of Plasma Bioelectrical Properties in Sepsis
timeFrame: through study completion, an average of 10 days
Secondary outcomes:
measure: Correlation Between Biophysical Parameters and Conventional Infection and Inflammation Biomarkers
timeFrame: through study completion, an average of 3 months
Other outcomes:
Locations:
city: Cosenza
country: Italy
facility: ''Annunziata'' Hospital
Study officials:
References:
Clinical trial NCT04266041: High-density EEG in Neurological Disorders
Official title: High-density EEG in Neurological Disorders
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Epilepsy
Tumor
Healthy
Keywords: Electroencephalogram (EEG)
Epilepsy
Lesion
Brain
Language
Movement
Sensation
Mapping
Dense-array EEG
High-density EEG
HD-EEG
stroke
Electrical Impedance Tomography
Lead sponsor: Dartmouth-Hitchcock Medical Center
Sponsor class: OTHER
First posted: 2020-02-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of the study is to use a new method of high-density electroencephalogram (HD-EEG) recording to map brain areas important for movement, sensation, language, emotion, and cognition.

Detailed description: This study will measure brain waves using high-density EEG. Participants will be asked wear a cap with electrodes attached to it. During the recording, participants may be asked to rest, sleep, or complete a task. The tasks involve viewing pictures, answering questions, speaking, or moving an arm or leg. Recordings generally last between 60-120 minutes.\*

Eligibility criteria: Inclusion Criteria:

* Able to perform the tasks
* Able to give own consent

Exclusion Criteria:

* Any neurologic or psychiatric diagnosis such as stroke, tumor, or psychosis judged to interfere with high-density EEG.

Primary outcomes:
measure: Localize brain functions in patients and healthy controls
timeFrame: At baseline for approximately 60 - 90 minutes
Secondary outcomes:
measure: Localize brain areas involved in language
timeFrame: At baseline for approximately 60 - 90 minutes
measure: Localize brain areas involved in movement
timeFrame: At baseline for approximately 60 - 90 minutes
measure: Localize brain areas involved in sensation
timeFrame: At baseline for approximately 60 - 90 minutes
measure: Localize brain areas involved in emotion
timeFrame: At baseline for approximately 60 - 90 minutes
measure: Localize brain areas involved in memory
timeFrame: At baseline for approximately 60 - 90 minutes
measure: Localize brain areas associated with lesions
timeFrame: At baseline for approximately 60 - 90 minutes
Other outcomes:
Locations:
city: Lebanon
country: United States
facility: Dartmouth-Hitchcock Medical Center
state: New Hampshire
Study officials:
References:
Clinical trial NCT01471041: Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
Official title: Vital Access Venous Window Needle Guide for Salvage of AV FistulaE (SAVE) Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: End Stage Renal Disease
AV Fistula
Kidney Failure
Keywords: End Stage Renal Disease
Hemodialysis
AV fistula
Kidney failure
Lead sponsor: Vital Access Corp.
Sponsor class: INDUSTRY
First posted: 2011-11-11
Enrollment: 54
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.


Eligibility criteria: Inclusion Criteria:

* Deep, uncannulatable, upper extremity arteriovenous fistula
* Minimum arteriovenous fistula flow 400 ml/min
* One year life expectancy

Exclusion Criteria:

* Non-transposed basilic or brachial vein arteriovenous fistula
* History of peripheral vascular disease
* History of cardiovascular disease
* History of cerebral vascular disease

Primary outcomes:
measure: Use of Venous Window Needle Guide to Obtain Arteriovenous Access for Hemodialysis
timeFrame: 3 months
Secondary outcomes:
measure: Arteriovenous Fistula Cannulation Complications While Using the Venous Window Needle Guide
timeFrame: 6 months
Other outcomes:
Locations:
city: Fresno
country: United States
facility: Ladenheim Dialysis Access Centers
state: California
city: Tulsa
country: United States
facility: University of Oklahoma - Tulsa
state: Oklahoma
Study officials:
affiliation: Vital Access
name: Mark Crawford, BA
role: STUDY_DIRECTOR
References:
citation: Jennings WC, Galt SW, Shenoy S, Wang S, Ladenheim ED, Glickman MH, Kathuria P, Browne BJ. The Venous Window Needle Guide, a hemodialysis cannulation device for salvage of uncannulatable arteriovenous fistulas. J Vasc Surg. 2014 Oct;60(4):1024-32. doi: 10.1016/j.jvs.2014.04.016. Epub 2014 May 13.